PL379705A1 - Czynniki do obrazowania - Google Patents

Czynniki do obrazowania

Info

Publication number
PL379705A1
PL379705A1 PL379705A PL37970504A PL379705A1 PL 379705 A1 PL379705 A1 PL 379705A1 PL 379705 A PL379705 A PL 379705A PL 37970504 A PL37970504 A PL 37970504A PL 379705 A1 PL379705 A1 PL 379705A1
Authority
PL
Poland
Prior art keywords
imaging agents
compounds
diseases
endometriosis
kaposi
Prior art date
Application number
PL379705A
Other languages
English (en)
Other versions
PL210122B1 (pl
Inventor
Alan Cuthbertson
Magne Solbakken
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Publication of PL379705A1 publication Critical patent/PL379705A1/pl
Publication of PL210122B1 publication Critical patent/PL210122B1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Light Receiving Elements (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nuclear Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL379705A 2003-07-30 2004-07-21 Oparte na peptydach związki, sposób i zestawy do ich wytwarzania, ich zastosowanie do diagnozowania oraz zawierające je preparaty radiofarmaceutyczne PL210122B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0317815.9A GB0317815D0 (en) 2003-07-30 2003-07-30 Imaging agents

Publications (2)

Publication Number Publication Date
PL379705A1 true PL379705A1 (pl) 2006-11-13
PL210122B1 PL210122B1 (pl) 2011-12-30

Family

ID=27799463

Family Applications (2)

Application Number Title Priority Date Filing Date
PL379705A PL210122B1 (pl) 2003-07-30 2004-07-21 Oparte na peptydach związki, sposób i zestawy do ich wytwarzania, ich zastosowanie do diagnozowania oraz zawierające je preparaty radiofarmaceutyczne
PL04743485T PL1648925T3 (pl) 2003-07-30 2004-07-21 Środki obrazujące na bazie bicyklicznych peptydów

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL04743485T PL1648925T3 (pl) 2003-07-30 2004-07-21 Środki obrazujące na bazie bicyklicznych peptydów

Country Status (23)

Country Link
US (2) US7410943B2 (pl)
EP (1) EP1648925B1 (pl)
JP (1) JP4625002B2 (pl)
KR (1) KR101153529B1 (pl)
CN (1) CN1829735B (pl)
AT (1) ATE442379T1 (pl)
BR (1) BRPI0412986A (pl)
CA (1) CA2533321C (pl)
CY (1) CY1109522T1 (pl)
DE (1) DE602004023092D1 (pl)
DK (1) DK1648925T3 (pl)
ES (1) ES2332722T3 (pl)
GB (1) GB0317815D0 (pl)
HU (1) HUP0600230A3 (pl)
IL (1) IL173029A0 (pl)
MX (1) MXPA06001090A (pl)
NO (1) NO20060825L (pl)
NZ (1) NZ544583A (pl)
PL (2) PL210122B1 (pl)
PT (1) PT1648925E (pl)
RU (2) RU2355702C2 (pl)
SI (1) SI1648925T1 (pl)
WO (1) WO2005012335A1 (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006491A2 (en) * 2001-07-10 2003-01-23 Amersham Health As Peptide-based compounds for targeting intergin receptors
GB0206750D0 (en) * 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
NO20033115D0 (no) * 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser
EP2905033B1 (en) 2003-12-16 2020-09-02 Nektar Therapeutics Monodisperse PEGylated naloxol compositions
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
CN102532264A (zh) * 2004-06-16 2012-07-04 通用电气医疗集团股份有限公司 基于肽的化合物
GB0420344D0 (en) 2004-09-14 2004-10-13 Amersham Plc Diagnostic compounds
ES2358745T3 (es) 2004-11-22 2011-05-13 Ge Healthcare As Agentes de contraste para señalar matriz extracelular.
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
EP1940841B9 (fr) 2005-10-07 2017-04-19 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
US8148575B2 (en) 2006-04-20 2012-04-03 Hammersmith Imanet Limited Radiofluorinated compounds and their preparation
CN105061577A (zh) 2006-12-14 2015-11-18 爱勒让治疗公司 双巯基大环化系统
EP2952522B1 (en) 2007-01-31 2019-10-30 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
ES2398310T3 (es) 2007-02-23 2013-03-15 Aileron Therapeutics, Inc. Péptidos macrocíclicos unidos a triazol
AU2008232709C1 (en) 2007-03-28 2015-01-15 President And Fellows Of Harvard College Stitched polypeptides
GB0722650D0 (en) * 2007-11-19 2007-12-27 Ge Healthcare Ltd Novel imaging method
CA2711678A1 (en) * 2008-01-09 2009-07-16 Molecular Insight Pharmaceuticals, Inc. Inhibitors of carbonic anhydrase ix
WO2009108484A1 (en) * 2008-02-28 2009-09-03 Ge Healthcare Limited Synthesis of a peg-6 moiety from commercial low-cost chemicals
GB0814722D0 (en) * 2008-08-12 2008-09-17 Ge Healthcare Ltd Treatment monitoring
MX2011003168A (es) * 2008-09-29 2011-05-19 Gilead Sciences Inc Combinaciones de un agente de control de cantidad y un antagonista del receptor a-2-alfa para utilizarse en metodos de tomografia computarizada de detectores multiples.
WO2010083347A2 (en) 2009-01-14 2010-07-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
GB0905438D0 (en) 2009-03-30 2009-05-13 Ge Healthcare Ltd Radiolabelling reagents and methods
GB0910013D0 (en) * 2009-06-10 2009-07-22 Ge Healthcare Ltd PET imaging of fibogenesis
US20130072439A1 (en) 2009-09-22 2013-03-21 Huw M. Nash Peptidomimetic macrocycles
WO2011084763A1 (en) 2009-12-21 2011-07-14 Ge Healthcare Limited Borosilicate glassware and silica based qma's in 18f nucleophilic substitution: influence of aluminum, boron and silicon on the reactivity of the 18f ion
KR20170058446A (ko) 2010-08-13 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
AU2011307608B8 (en) 2010-09-30 2015-08-27 Grünenthal GmbH Crystalline naloxol-PEG conjugate
FR2967671A1 (fr) * 2010-11-24 2012-05-25 Pf Medicament Complexe de technetium 99m en tant qu'outil de diagnostic in vivo des tumeurs cancereuses
AR088392A1 (es) 2011-10-18 2014-05-28 Aileron Therapeutics Inc Macrociclos peptidomimeticos
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CA2862038C (en) 2012-02-15 2021-05-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
SG11201702175YA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對pd-l1之抗體分子及其用途
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
GB201511036D0 (en) 2015-06-23 2015-08-05 Guy S And St Thomas Hospital Nhs Foundation Trust Imaging method
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. Mcl−1のモジュレーターとしてのペプチド模倣大環状分子
GB201621864D0 (en) * 2016-12-21 2017-02-01 Ge Healthcare Ltd Solid phase conditioning
CN113000001A (zh) * 2021-03-22 2021-06-22 洛阳海惠新材料股份有限公司 一种用于制备pbat的增粘连体反应器
CN113750923A (zh) * 2021-08-30 2021-12-07 桐昆集团浙江恒腾差别化纤维有限公司 一种酯化反应回收系统

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2774378B2 (ja) * 1991-02-08 1998-07-09 ダイアテク,インコーポレイテッド 映像用テクネチウム−99m標識化ポリペプチド
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
CN1230441C (zh) * 2000-04-12 2005-12-07 安盛药业有限公司 结合整联蛋白的肽衍生物
RU2165266C1 (ru) * 2000-06-28 2001-04-20 Центральный научно-исследовательский рентгенорадиологический институт Способ получения [2-18f]-2-дезоксиглюкозы
AU2001288847A1 (en) * 2000-09-07 2002-03-22 Biosyntema Inc. Conformationally constrained labeled peptides for imaging and therapy
IL141276A0 (en) * 2001-02-05 2002-03-10 Peptor Ltd Backbone cyclized radiolabelled somatostatin analogs
WO2003006491A2 (en) * 2001-07-10 2003-01-23 Amersham Health As Peptide-based compounds for targeting intergin receptors

Also Published As

Publication number Publication date
CN1829735A (zh) 2006-09-06
IL173029A0 (en) 2006-06-11
US7410943B2 (en) 2008-08-12
SI1648925T1 (sl) 2010-01-29
US20080267881A1 (en) 2008-10-30
RU2009105640A (ru) 2010-08-27
PL1648925T3 (pl) 2010-02-26
WO2005012335A1 (en) 2005-02-10
DE602004023092D1 (de) 2009-10-22
BRPI0412986A (pt) 2006-10-03
PT1648925E (pt) 2009-12-10
CA2533321A1 (en) 2005-02-10
NO20060825L (no) 2006-03-29
HUP0600230A3 (en) 2009-09-28
NZ544583A (en) 2009-12-24
US7811551B2 (en) 2010-10-12
DK1648925T3 (da) 2010-01-04
ATE442379T1 (de) 2009-09-15
CA2533321C (en) 2012-09-18
RU2006102324A (ru) 2007-09-20
RU2355702C2 (ru) 2009-05-20
HUP0600230A2 (en) 2007-01-29
EP1648925A1 (en) 2006-04-26
CY1109522T1 (el) 2014-08-13
HK1097278A1 (en) 2007-06-22
ES2332722T3 (es) 2010-02-11
CN1829735B (zh) 2010-05-26
KR20060090795A (ko) 2006-08-16
GB0317815D0 (en) 2003-09-03
EP1648925B1 (en) 2009-09-09
KR101153529B1 (ko) 2012-06-11
PL210122B1 (pl) 2011-12-30
JP4625002B2 (ja) 2011-02-02
JP2007523880A (ja) 2007-08-23
MXPA06001090A (es) 2006-04-24
US20060193773A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
GB0317815D0 (en) Imaging agents
AU9245601A (en) Peptide-based compounds
MXPA04000173A (es) Compuestos basados en peptidos.
DE602004026053D1 (pl)
NO20022655L (no) <Beta>-2-adrenerge reseptoragonister
NZ521735A (en) Peptide-based compounds, their use as targeting vectors that bind to receptors associated with antiogenesis such as integrin receptors
EA200300441A1 (ru) Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
MX2009012579A (es) Antagonistas piridil piperidina del receptor de orexina.
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
BRPI0409701A (pt) ligantes de receptores de canabinóides e seus usos
TW200510429A (en) Heterocyclic MCHR1 antagonists
PT1696905E (pt) 2-aminotetralinas substituídas para o tratamento preventivo da doença de parkinson
EP1178988A4 (en) THERAPEUTIC COMPOUNDS AND METHODS
DE60230683D1 (de) 3,6-disubstituierte azabicyclo-3.1.0 hexan-derivat
ATE306283T1 (de) Biotin-derivate und ihre konjugaten mit chelatierungsmitteln
DE50006244D1 (en) Neue substituierte 3-phenoxy- und 3-phenylalkyloxy-2-phenyl-propylamine
PL2101826T3 (pl) Znakowane izotopowo związki na bazie peptydów i ich zastosowania

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20130721